首页> 外文期刊>Journal of vascular and interventional radiology: JVIR >Intraarterial Therapy with a New Potent Inhibitor of Tumor Metabolism (3-bromopyruvate): Identification of Therapeutic Dose and Method of Injection in an Animal Model of Liver Cancer
【24h】

Intraarterial Therapy with a New Potent Inhibitor of Tumor Metabolism (3-bromopyruvate): Identification of Therapeutic Dose and Method of Injection in an Animal Model of Liver Cancer

机译:一种新的有效的肿瘤代谢抑制剂(3-溴丙酮酸盐)的动脉内治疗:在肝癌动物模型中的治疗剂量和注射方法鉴定

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: A potent new adenosine triphosphate inhibitor-3-bromopyruvate (3-BrPA)-has been shown to have antitumor effects when injected intraarterially in the hepatic artery of rabbits with VX-2 tumors. The authors performed a stepwise study in rabbits to determine the therapeutic dose and method of delivery of 3-BrPA. MATERIALS AND METHODS: White New Zealand rab>its with VX-2 tumors were used for this study. Eight animals were examined to establish the maximum tolerated dose (2.5 or 5.0 mmol/L of 25-mL 3-BrPA) as a single bolus injection. The 2.5 mmol/L dose was then used to compare three methods of delivery: injection of one bolus, two 12.5-mL serial bolus injections administered 1 hour apart, and continuous infusion of 25 mL for 1 hour. Finally, dose-response analysis was performed by using 10 groups of three animals each, with 1-hour intraarterial infusions of 3-BrPA (25 mL) at incremental doses of 0.25 mmol/L (range, 0.5-2.5 mmol/L) with phosphate buffered saline used for control animals. All animals were sacrificed at 48 hours, and histopathologic analysis was performed, x~2 statistics were used to analyze the data. RESULTS: The maximum tolerated dose of 3-BrPA was 2.5 mmol/L; however, it caused substantial peripheral liver necrosis. These effects were minimized when 3-BrPA was infused over 1 hour. Complete tumor necrosis was identified in all samples with at least 2.0 mmol/L of 3-BrPA. The 1.75 mmol/L concentration was identified as therapeutic because it caused complete tumor apoptosis and minimal toxicity (P < .001). CONCLUSIONS: The results identified both the therapeutic dose (1.75 mmol/L) and the method of infusion (1 hour intraarterial infusion) of 3-BrPA. This potent new treatment may prove to be an effective way of treating liver cancer and may become part of a new class of anticancer drugs based on the inhibition of tumor metabolism.
机译:用途:一种有效的新型三磷酸腺苷抑制剂-3-溴丙酮酸(3-BrPA)-经动脉内注射到患有VX-2肿瘤的兔肝动脉中具有抗肿瘤作用。作者在兔子中进行了逐步研究,以确定3-BrPA的治疗剂量和递送方法。材料与方法:本研究采用新西兰白兔及其VX-2肿瘤。检查八只动物以建立单次大剂量注射的最大耐受剂量(2.5或5.0 mmol / L的25 mL 3-BrPA)。然后将2.5 mmol / L剂量用于比较三种递送方法:一次推注,两次间隔1小时给药的12.5 mL连续推注以及25 mL连续输注1小时。最后,通过使用每组三只动物的10组进行剂量-反应分析,以0.25 mmol / L(0.5-2.5 mmol / L)的增量剂量向动脉内输注3-BrPA(25 mL)1小时。用于对照动物的磷酸盐缓冲盐水。在48小时处死所有动物,并进行组织病理学分析,使用x〜2统计量分析数据。结果:3-BrPA的最大耐受剂量为2.5 mmol / L。但是,它引起了周围性肝坏死。当在1小时内注入3-BrPA时,这些影响最小化。在所有样品中,至少含有2.0 mmol / L的3-BrPA,均发现肿瘤完全坏死。 1.75 mmol / L的浓度被确定为可治疗的,因为它引起了完整的肿瘤细胞凋亡和最小的毒性(P <.001)。结论:结果确定了3-BrPA的治疗剂量(1.75 mmol / L)和输注方法(1小时动脉内输注)。这种有效的新疗法可能被证明是治疗肝癌的有效方法,并可能基于抑制肿瘤代谢而成为一类新的抗癌药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号